A promising codrug of nicotinic acid and ibuprofen for managing dyslipidemia. I: Synthesis and in vitro evaluation

References

• Mahley R, Bersot T. (2006). Drug therapy for hypercholesterolemia and dyslipidemia. In Brunton L, Lazo J, Parker K. (eds.) Goodman & Gilman’s: the pharmacological basis of therapeutics 11th edn. New York, McGraw-Hill. 933–966.
   Google Scholar
• Cenedella RJ. (2003). Hypocholesterolemic drugs and coronary heart disease. In Craig CR, Stitzel RE. (eds.) Modern pharmacology with clinical applications. 6th edn. USA, Lippincott Williams & Wilkins.
   Google Scholar
• Menon D, Dollimore D, Alexander KS. (2002). A TG–DTA study of the sublimation of nicotinic acid. Thermochimica Acta, 392–393, 237–241.
   Web of Science ®Google Scholar
• Bodor ET, Offermanns S. (2008). Review: Nicotinic acid: an old drug with a promising future. Bjp, 153:s68–s75
   PubMed Web of Science ®Google Scholar
• Sampathkumar K, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RNP. (2006). Extended release nicotinic acid− a novel oral agent for phosphate control. Int Urol Nephrol, 38:171–174.
   PubMed Web of Science ®Google Scholar
• Carlson LA. (2005). Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med, 258:94–114.
   PubMed Web of Science ®Google Scholar
• Kuo PT, Kostis JB, Moreyra AE, Hayes JA. (1981). Familial type II hyperlipoproteinemia with coronary heart disease: effect of diet-colestipol-nicotinic acid treatment. Chest, 79:286–291.
   PubMed Web of Science ®Google Scholar
• Offermanns S. (2006). The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol Sci, 27:384–390.
   PubMed Web of Science ®Google Scholar
• Brown BG. (2007). Expert commentary: niacin safety. Am J Cardiol, 99:32–c34c
   PubMed Web of Science ®Google Scholar
• Kamanna VS, Kashyap ML. (2008). Mechanism of action of niacin. Am J Cardiol, 101:20–b26b.
   PubMed Web of Science ®Google Scholar
• Gille A, Bodor ET, Ahmed K, Offermanns S. (2008). Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol, 48:79–106.
   PubMed Web of Science ®Google Scholar
• Davidson MH. (2008). Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Am J Cardiol, 101:14–b19b.
   PubMed Web of Science ®Google Scholar
• Jungnickel PW, Maloley PA, Vander-Tuln EL, Peddlcord TE, Campbell JR. (1997). Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med, 12:591–596.
   PubMed Web of Science ®Google Scholar
• Obertwittler H, Baccara-Dinet M. (2006). Review: Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Int J Clin Pract, 60:707–715.
   PubMed Web of Science ®Google Scholar
• Cefali EA, Simmons PD, Stanek EJ, Mcgovern ME, Kissling CJ. (2007). Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int J Clin Pharmacol Therapeut, 45:78–88.
   PubMed Web of Science ®Google Scholar
• Teng XW, Wang SWJ, Davies NM. (2003). Stereospecific high-performance liquid chromatographic analysis of ibuprofen in rat serum. J Chromatog B, 796:225–231.
   PubMed Web of Science ®Google Scholar
• De Brabander C, Vervaet C, Van Bortel L, Remon JP. (2004). Bioavailability of ibuprofen from hot-melt extruded mini-matrices. Int j Pharm, 271:77–84.
   PubMed Web of Science ®Google Scholar
• Babazadeh M. (2006). Synthesis and study of controlled release of ibuprofen from the new acrylic type polymers. Int j Pharm, 316:68–73.
   PubMed Web of Science ®Google Scholar
• Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP et al. (2005). Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. j Pharm Sci, 94:2121–2131.
   PubMed Web of Science ®Google Scholar
• Hamoudov’a R, Posp’iˇsilov’a M. (2006). Determination of ibuprofen and flurbiprofen in pharmaceuticals by capillary zone electrophoresis. J Pharm Biomed Anal, 41:1463–1467.
   PubMed Web of Science ®Google Scholar
• Lana W, Zhua H, Zhoua Z, Ye C, Liu M. (2007). 1H-NMR investigation on interaction between ibuprofen and lipoproteins. Cpl 148:105–111.
   Google Scholar
• Foxworthy PS, Perry DN, Eacho PJ. (1993). Induction of peroxisomal Β-oxidation by nonsteroidal anti-inflammatory drugs. Toxicol Appl Pharamcol, 118:271–274.
   PubMed Web of Science ®Google Scholar
• Sun Y, Takaba K, Kido H, Nakashima MN, Nakashima K. (2003). Simultaneous determination of arylpropionic acidic nonsteroidal anti-inflammatory drugs in pharmaceutical formulations and human plasma by HPLC with UV detection. J Pharm Biomed Anal, 30:1611–1619.
   PubMed Web of Science ®Google Scholar
• Abdellatif KRA, Chowdhury MA, Ying Dong DD, Yu G, Velázquez CA, Suresh MR, Knaus EE. (2009). Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: synthesis, biological evaluation and nitric oxide release studies. Bioorg Med Chem Lett, 19:3014–3018.
   PubMed Web of Science ®Google Scholar
• Zhao X-G, Wei D-Z, Song Q-X. (2005). A facile enzymatic process for the preparation of ibuprofen ester prodrug in organic media. J Mol Catal B: Enzym, 36:47–53.
   Web of Science ®Google Scholar
• Bhosle D, Bharambe S, Gairola N, Dhaneshwar SS. (2006). Mutual prodrug concept: fundamentals and applications. Indian J Pharm Sci, 68:286–294.
   Google Scholar
• Friedel HA, Campoli-Richards DM, Goa KL. (1989). Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs, 37:491–522.
   PubMed Web of Science ®Google Scholar
• Rogers HJ, Bradbrook ID, Morrison PJ, Spector RG, Cox DA, Lees LJ. (1983). Pharmacokinetics and bioavailability of sultamicillin estimated by high performance liquid chromatography. J Antimicrob Chemother, 11:435–445.
   PubMed Web of Science ®Google Scholar
• Ganesh S, Das G, Atignal S, Mazumdar-Shaw K. (2005). Salt of atorvastatin with ranitidine. In Limited B. (ed.) PCT Int Appl. WO 2005023764 A1. (PATENT).
   Google Scholar
• Chang G, Hamanaka ES, Lamattina JL. (2002). Mutual prodrugs of amlodipine and atorvastatin. US, Pfizer. US Patent 6,486,182 B1.
   Google Scholar
• Tendolkar A, Palani A, Huang X, Aslanian RG. (2010). Niacin derivatives useful to treat metabolic syndromes. In Schering (ed.) International search report (art 21(3)). US PCT Int Appl. WO 2010/009212 A1.
   Google Scholar
• Kaufman JG. (1945). Nicotinic acid esters. J Am Chem Soc, 67:497–498.
   Web of Science ®Google Scholar
• Rittirod T, Hatanaka T, Kagami N, Katayama K, Koizumi T. (1999). Simultaneous transport and metabolism of nicotinic acid derivatives in hairless mouse skin. Biol Pharm Bull, 22:305–309.
   PubMed Web of Science ®Google Scholar
• Jacobson EL, H Kim2 MK, Wondrak GT, Jacobson MK. (2008). Developing topical prodrugs for skin cancer prevention. In Alberts DS, Hess LM. (eds.) Fundamentals of cancer prevention. 2nd edn. Arizona (USA), Springer Berlin Heidelberg.
   Google Scholar
• Tashtoush BM, Kim H, Jacobson EL, Jacobson MK. (2007). Formulation compatibility of myristyl nicotinate with drugs used to treat dermatological conditions involving an impaired skin barrier. Drug Dev Ind Pharm, 33:1176–1182.
   PubMed Web of Science ®Google Scholar
• Mendes E, Furtado T, Neres J, Iley J, Jarvinen T, Rautio J et al. (2002). Synthesis, stability and in vitro dermal evaluation of aminocarbonyloxymethyl esters as prodrugs of carboxylic acid agents. Bioorg Med Chem, 10:809–816.
   PubMed Web of Science ®Google Scholar
• Hsu CH, Jay M, Bummer PM, Lehmler HJ. (2003). Chemical stability of esters of nicotinic acid intended for pulmonary administration by liquid ventilation. Pharm Res, 20:918–925.
   PubMed Web of Science ®Google Scholar
• Zhao X, Tao X, Wei D, Song Q. (2006). Pharmacological activity and hydrolysis behavior of novel ibuprofen glucopyranoside conjugates. Eur j Med Chem, 41:1352–1358.
   PubMed Web of Science ®Google Scholar
• Khan MS, Akhter M. (2005). Synthesis, pharmacological activity and hydrolytic behavior of glyceride prodrugs of ibuprofen. Eur j Med Chem, 40:371–376.
   PubMed Web of Science ®Google Scholar
• Maag H. (2007). Prodrugs of carboxylic acids. In Stella, VJ, Borchardt RT, Hagemen MJ, Oliyai R, Maag H, Tilley JW. (eds.) Prodrugs: challenges and rewards part 1. USA, Springer Science and Business Media. 3–30
   Google Scholar
• Chatterjee NR, Kulkarni AA, Ghulekar SP. (2008). Synthesis, pharmacological activity and hydrolytic behavior of ethylenediamine and benzathine conjugates of ibuprofen. Eur j Med Chem, 43:2819–2823.
   PubMed Web of Science ®Google Scholar
• Reddy A, Hashim M, Wang Z, Penn L, Stankovic CJ, Burdette D et al. (2007). A novel method for assessing inhibition of ibuprofen chiral inversion and its application in drug discovery. Int J Pharm, 335:63–69.
   PubMedGoogle Scholar
• Head KA. (1996). Inositol hexaniacinate: a safer alternative to niacin. Alt Med Rev, 1:176–184.
   Google Scholar
• Herrera E, Lasunción MA, Castro M, Gómez-Coronado D, Martín A, Quack G. (1988). Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism. Biochim Biophys Acta, 963:42–52.
   PubMed Web of Science ®Google Scholar
• Abu-Zanat FZ, Qandil A, Tashtoush B. (2010). Simultaneous RP-LC determination of ibuprofen, ibuprofen 2-hydroxyethyl ester, and ibuprofen 2-hydroxyethyl ester− nicotinic acid codrug in aqueous solutions and biological samples. Manuscript accepted in Chromatogrphia 2011
   Google Scholar
• Puntel RL, Roos DH, Paix˜ao MAW, Braga AOL, Zeni G, Nogueira CW, Rocha JBT. (2007). Oxalate modulates thiobarbituric acid reactive species (tbars) production in supernatants of homogenates from rat brain, liver and kidney: effect of diphenyl diselenide and diphenyl ditelluride. Chem-Biol Interac, 165:87–98.
   PubMed Web of Science ®Google Scholar
• Higgins JD, Gilnor TP, Martelluci SA, Bruce RD, Brittain HG. (2001). ibuprofen. In Brittain HG. (ed.) Analytical profiles of drug substances and excipients. USA, Academic Press.
   Google Scholar
• Perlovich GL, Kurkov SV, Kinchin AN, Bauer-Brandl A. (2004). Solvation and hydration characteristics of ibuprofen and acetylsalicylic acid. Aaps Pharmsci, 6:22–30.
   Google Scholar
• Yazdanian M, Briggs K, Jankovsky C, Hawi A. (2004). The “high solubility” definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. Pharm Res, 21:293–299.
   PubMed Web of Science ®Google Scholar
• Yalkowsky SH, He Y. (2003). Handbook of aqueous solubility data, US, CRC Press.
   Google Scholar
• Sigma-Aldrich. (2008). Nicotinic acid material safety sheet. USC upstate. 650–651
   Google Scholar
• Kopelevich VM, Gunar VI. (1999). Search for new drugs: some approaches to the directed search for new drugs based on nicotinic acid. Pharm Chem J, 33:177–187.
   Google Scholar
• Davaran S, Rashidi MR, Hanaee J, Hamidi AA, Hashemi M. (2006). Synthesis and hydrolytic behavior of ibuprofen prodrugs and their PEGylated derivatives. Drug Deliv, 13:383–387.
   PubMed Web of Science ®Google Scholar
• Mørk N, Bundgaard H. (1992). Stereoselective enzymatic hydrolysis of various ester prodrugs of ibuprofen and flurbiprofen in human plasma. Pharm Res, 9:492–496.
   PubMed Web of Science ®Google Scholar
• Kourounakis A. P., Victoratos P., Peroulis N., Stefanou N., Yiangou M., Hadjipetrou L. & Kourounakis P. N.. (2002). Experimental Hyperlipidemia and the Effect of NSAIDs. Exp Mol Pathol, 73:135–138.
   PubMed Web of Science ®Google Scholar